Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Applied Microbiology|October 1, 1974
Ehrlich ascites tumor preservation for fifteen years--a simple methodW A Cassel, K M McCaskillMedical Oncology and Tumor Pharmacotherapy|January 1, 1992
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysateW A Cassel, D R MurrayInfection and Immunity|March 1, 1972
Biological activity of a partially purified inhibitor of vaccinia virus hemagglutininS C Lau, W A CasselLaboratory Investigation; a Journal of Technical Methods and Pathology|November 11, 1975
The pathogenesis of Vaccinia virus toxicity. II. An electron microscopic studyH M Sottnek, W G Campbell, W A CasselLaboratory Investigation; a Journal of Technical Methods and Pathology|November 11, 1975
The pathogenesis of Vaccinia virus toxicity. I. The role of virus-platelet interactionH M Sottnek, W A Cassel, W G CampbellCancer|September 1, 1983
A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysateW A Cassel, D R Murray, H S PhillipsCancer|April 1, 1986
Malignant melanoma. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysateW A Cassel, K M Weidenheim, W G Campbell, et al.Cancer|August 1, 1977
Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responsesW A Cassel, D R Murray, A H Torbin, et al.Cancer|August 1, 1977
Viral oncolysate in the management of malignant melanoma. II. Clinical studiesD R Murray, W A Cassel, A H Torbin, et al.Pageof 1